Characterization of Genomic Alterations, Tumor Mutational Burden and PDL1 Expression in 181 Chinese Hepatocellular Carcinomas.
Qi Ling,Pingzhou Yang,Xiaofeng Tang,Defei Hong,Linlin Qu,Yujie Feng,Yimeng Ou,Yong Li,Yujun Shi,Chunwen Xiao,Yanlin Li,Kai Wang,Weifeng Wang,Hong Bu
DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.e24276
IF: 45.3
2018-01-01
Journal of Clinical Oncology
Abstract:e24276 Background: Hepatocellular carcinoma (HCC), the most common hepatic malignancy, is the second leading cause of cancer-related death worldwide. China accounts for more than 50% of new HCC cases and deaths in the world. The genomic profiles of HCC in Chinese patients had not been thoroughly elucidated to facilitate diagnosis and treatment. Methods: FFPE tumor and matched blood samples of 181 Chinese HCC patients, including 152 males (median age of 54) and 29 females (median age of 52), were collected for next-generation sequencing-based 450 genes panel assay. Genomic alterations (including single base substitutions, short and long insertions/deletions, copy number variations, and gene rearrangement in selected genes) and tumor mutational burden were assessed. In addition, the expression of tumor cell PDL1 was also evaluated by FDA-cleared DAKO 22c3 antibody. Results: The most frequently mutated genes in 181 Chinese HCC were TP53 (59.7%), TERT (34.3%), CTNNB1 (21.5%), AXIN1 (12.2%), RB1 (11.0%), STK24 (11.0%), ARID1A (9.9%), CCND1 (7.7%), TSC2 (6.6%) and FGF19 (6.6%). The mutation rates of TERT (p = 0.027) and RB1 (p = 0.016) were significantly higher in patients (pts) with TMB greater than the cohort medium of 7.2 muts/Mb. In addition, loss of function mutation of PBRM1 was found in 2.8% of the pts. About 7% of the patients had TMB value higher than 20 muts/Mb, compared to 1-2% in Western HCC pts, and 31% higher than 10 muts/Mb. Seventy-four patients (median age 54 years; median TMB 6.8 muts/Mb) had tumorous PDL1 expressions assessed by IHC assay. Thirty-six percent of patients were positive of PDL1 (tumor portion score TPS greater than 1%). Only three pts possessed both high TMB and high PDL1 expression (TPS > 50). No correlation was observed between the expression of PDL1 and TMB (r = 0.1). Conclusions: This is the first genomic profiling study of Chinese HCC pts along with TMB and PDL1 expression results. With less actionable gene alterations but more often high TMB and PDL1 expression than their Western counterparts, Chinese HCC pts could potentially benefit more from immune check point inhibitor-based therapies. However, no correlation was observed between the expressions of PDL1 and TMB values.